福建榕基软件股份有限公司（以下简称"公司"）基于整体战略部署及实际经营需求，于2025年10月28日 召开第六届董事会第二十一次会议，审议通过《关于清算注销控股子公司的议案》，同意对控股子公司 福建容大物联网科技有限公司（以下简称"容大物联"）实施清算注销，具体内容详见公司于2025年10月 29日在巨潮资讯网（www.cninfo.com.cn）披露的《关于清算注销控股子公司的公告》（公告编号： 2025-032）。 近日，公司收到福州市市场监督管理局出具的《登记通知书》，容大物联已完成注销登记手续。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002474 证券简称：榕基软件 公告编号：2025-045 福建榕基软件股份有限公司 关于控股子公司注销完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 本次注销完成后，容大物联不再纳入公司合并财务报表范围。本次注销不会对公司整体业务发展产生实 质性影响，不存在损害公司及全体股东特别是中小股东利益的情形。 特此公告。 福建榕基软件股份有限公司董事会 2025年12月20日 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 截至目前，亚振家居股份有限公司（以下简称"公司"）控股股东吴涛先生没有在未来36个月内改变公 司主营业务或者对主营业务做出重大调整的明确计划，或对公司及其子公司的主要资产和业务进行出 售、合并、与他人合资或合作的明确计划，或公司拟购买或置换资产的明确重组计划，或将其控制的其 他资产通过公司借壳上市的计划或安排。 ● 公司股票于2025年12月17日、18日、19日连续三个交易日内日收盘价格涨幅偏离值累计达到12%，属 于股票交易异常波动。 ● 生产经营风险。公司2025年前三季度归属于上市公司股东的净利润为-3,141.23万元，归属于上市公司 股东的扣除非经常性损益的净利润为-3,355.48万元，实现营业收入15,833.65万元（未审计）。公司股票 已于2025年5月6日起被实施退市风险警示。若公司2025年度经审计的扣除非经常性损益后的净利润为负 值，且扣除与主营业务无关的业务收入和不具备商业实质的收入 ...

公 告 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002641 证券简称：公元股份 公告编号：2025-046 公元股份有限公司 第六届董事会第十八次会议决议 三、备查文件 1、公司第六届董事会第十八次会议决议。 本公司及董事会全体成员保证本公告信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或 重大遗漏 一、会议召开情况 公元股份有限公司（下称"公司"）第六届董事会第十八次会议于2025年12月19日上午9：00以通讯方式 召开。会议通知（包括拟审议议案）已于2025年12月16日以通讯方式发出。本次董事会应到董事9名， 实际参加表决9名，高级管理人员列席了会议。会议由公司董事长卢震宇先生主持。会议程序符合有关 法律、法规、规范性文件及《公司章程》的规定。 二、会议决议情况 （一）以9票同意，0票反对，0票弃权的表决结果审议通过了《关于华东区域业务整合及全资子公司产 线搬迁的议案》。 《关于华东区域业务整合及全资子公司产线搬迁的公告》详见公司于2025年12月20日刊载于《证券时 报》《中国证券报》和 巨潮资讯网（http://www.cninfo.com.cn）。 公元股份有限公 ...

Core Viewpoint - The company has made significant decisions regarding the adjustment of fundraising project investments and the provision of loans to its subsidiary to ensure the smooth implementation of its projects [11][18]. Group 1: Board Meeting Decisions - The company held its 26th meeting of the 7th Board of Directors on December 19, 2025, where all 9 attending directors approved the resolutions [1][3]. - The board approved the adjustment of the fundraising project investment amount based on the actual net amount raised, which does not constitute a change in the use of funds [11][14]. - The board also approved the use of raised funds to provide loans to its subsidiary, Anhui Sugou Expressway Co., Ltd., for the implementation of the "Suzhou to Guzhen Expressway Project" [18][27]. Group 2: Fundraising Details - The company raised a total of RMB 1,548,584,019.18 through the issuance of 380,487,474 shares at a price of RMB 4.07 per share, with a net amount of RMB 1,532,236,775.42 after deducting issuance costs [11][18]. - The funds have been fully received and verified by Sigma Accounting Firm [11][18]. Group 3: Loan Provision to Subsidiary - The company will provide a loan of up to RMB 119,000.00 million to Anhui Sugou, which will be used exclusively for the expressway project and must be repaid within 12 months [21][27]. - The loan interest rate will be based on the one-year LPR rate published by the People's Bank of China on the day before the loan is issued [21][27]. Group 4: Compliance and Oversight - The adjustments and loan provisions have been reviewed and approved by the company's audit committee, confirming compliance with relevant laws and regulations [15][28]. - The company has established a three-party supervision agreement with its sponsor and the bank holding the raised funds to ensure proper management and usage of the funds [12][25].

证券代码：603713 证券简称：密尔克卫 公告编号：2025-097 转债代码：113658 转债简称：密卫转债 密尔克卫智能供应链服务集团 股份有限公司股东提前终止减持计划 暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 股东持股的基本情况 在本次减持计划实施前，北京君联茂林股权投资合伙企业（有限合伙）（以下简称"君联茂林"）持有密 尔克卫智能供应链服务集团股份有限公司（以下简称"公司"）股份1,616,613股，占减持计划公告披露时 公司总股本的1.02%。 2025年9月26日，公司披露了《密尔克卫智能供应链服务集团股份有限公司股东减持股份计划公告》 （公告编号：2025-084），君联茂林计划通过上海证券交易所交易系统以大宗交易、集中竞价交易方式 减持公司股份数量不超过1,616,613股，即减持不超过减持计划公告披露时公司总股本的1.02%。其中， 以大宗交易方式减持的股份数量不超过56,000股，以集中竞价交易方式减持的股份数量不超过1,560,613 股。 截至 ...

一、对外投资事项前期公告情况 2025年12月12日，云南临沧鑫圆锗业股份有限公司（以下简称"公司"）第八届董事会第三十二次会议审 议通过《关于对外投资设立控股子公司的议案》，同意公司与昆明哈傈佤企业管理合伙企业（有限合 伙）共同出资1,000万元设立控股子公司云南锗业生物科技有限公司（暂定名，以工商登记信息为 准）。 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性陈述或重大遗漏。 成立日期：2025年12月18日 住所：云南省昆明高新技术产业开发区马金铺街道办事处大营社区居委会魁星街666号 经营范围：许可项目：化妆品生产；第三类医疗器械生产；第三类医疗器械经营；检验检测服务；消毒 剂生产（不含危险化学品）；用于传染病防治的消毒产品生产。（依法须经批准的项目，经相关部门批 准后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件为准） 一般项目：细胞技术研 发和应用；生物化工产品技术研发；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推 广；化妆品批发；化妆品零售；技术进出口；货物进出口；健康咨询服务（不含诊疗服务）；日用化学 产品制造；基础化学原料制造（不含危险化学 ...

Group 1: Appointment of Senior Management - The company appointed Mr. Yao Zhichao as the Vice General Manager and Mr. Gong Huiming as the Secretary of the Board, effective from December 19, 2025, until the end of the sixth board term [1][18] - Mr. Gong Huiming will no longer serve as the Securities Affairs Representative, with Mr. Hu Feng appointed to this role [1][18] - The appointments were made to ensure the board's proper operation and governance structure, following relevant laws and company regulations [1][2] Group 2: Resignation of Senior Management - Ms. Lei He submitted her resignation as Secretary of the Board due to work reasons, effective upon delivery of her resignation letter to the board [3] - Her departure will not affect the normal operations of the board or the company, and she has completed the necessary handover procedures [3] Group 3: Cash Management Authorization - The company plans to use idle self-owned funds for cash management, with an authorization limit of up to RMB 2.5 billion [5][20] - The funds will be used for low-risk financial products, including time deposits, large certificates of deposit, and other safe investment options [5][10] - The authorization is valid until December 31, 2026, and the chairman is authorized to review the investments [12][20] Group 4: Board Meeting Details - The second temporary board meeting of 2025 was held on December 19, 2025, with all nine directors present, making the meeting legally valid [18] - Both the appointment of senior management and the cash management authorization were unanimously approved by the board [18][20]

Core Viewpoint - The company is undergoing a potential change in control due to its major shareholder, Quanzhou Hetian Investment Partnership, and its actual controller, Mr. Li Lin, planning to alter the company's control structure, which may lead to changes in the actual controller and major shareholder [2][3]. Group 1: Control Change Planning - The company received notification on December 19, 2025, regarding the planning of a control change by its major shareholder and actual controller [2]. - The specific transaction plans and agreements are currently under discussion and verification among the involved parties [2][3]. - There is uncertainty regarding the implementation and outcome of the planned significant matters [2][3]. Group 2: Stock Suspension - The company's stock (Tian Chuang Fashion, stock code: 603608) will be suspended from trading starting December 22, 2025, due to the ongoing planning of the control change [3]. - The company's convertible bonds (Tian Chuang Convertible Bonds, bond code: 113589) will also be suspended from trading and conversion starting on the same date [3]. - The expected duration of the suspension is no more than two trading days, and the company will fulfill its information disclosure obligations during this period [3].

本次控制权变更已获株洲市人民政府国有资产监督管理委员会同意批准，具体内容见公司2025年11月26 日披露的《关于收到株洲市国资委批复暨公司控制权拟发生变更的进展公告》（公告编号：2025- 040）。 二、本次股份过户完成情况 本次股份协议转让事项已通过深圳证券交易所合规性确认。2025年12月19日，中国证券登记结算有限责 任公司深圳分公司出具了《证券过户登记确认书》，本次转让股份已完成过户登记手续，过户日期为 2025年12月18日。 本次股份协议转让过户前后，各方持股数量及表决权变动情况如下： 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 旷达科技集团股份有限公司（以下简称"公司"）于2025年12月19日收到沈介良和株洲启创一号产业投资 合伙企业（有限合伙）（以下简称"株洲启创"）通知，沈介良向株洲启创协议转让公司股份事项已完成 股份过户登记手续，并取得了中国证券登记结算有限责任公司深圳分公司出具的《证券过户登记确认 书》。现将具体情况公告如下： 一、本次权益变动概述 公司原控股股东、实际控制人沈介 ...

Core Viewpoint - Shenzhen Sinopharm Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0137, aimed at treating elevated lipoprotein(a) levels, which are independent risk factors for cardiovascular diseases [1][2]. Group 1: Clinical Trial Approval - The company has been granted a Clinical Trial Approval Notice for SAL0137, allowing it to conduct clinical trials for treating elevated lipoprotein(a) levels [1]. - Elevated lipoprotein(a) is linked to various cardiovascular diseases, including coronary heart disease and ischemic stroke, increasing the risk through multiple mechanisms [1]. Group 2: Potential Impact and Development - If SAL0137 is successfully developed and approved, it could provide new treatment options for patients and address unmet clinical needs, enhancing the company's product pipeline in chronic disease management [2]. - The company will conduct clinical trials in accordance with national drug registration regulations, and the timeline from clinical trials to market approval is subject to various uncertainties, which may not have an immediate impact on the company's performance [2].